| Literature DB >> 29632055 |
Al B Benson, Alan P Venook, Mahmoud M Al-Hawary, Lynette Cederquist, Yi-Jen Chen, Kristen K Ciombor, Stacey Cohen, Harry S Cooper, Dustin Deming, Paul F Engstrom, Ignacio Garrido-Laguna, Jean L Grem, Axel Grothey, Howard S Hochster, Sarah Hoffe, Steven Hunt, Ahmed Kamel, Natalie Kirilcuk, Smitha Krishnamurthi, Wells A Messersmith, Jeffrey Meyerhardt, Eric D Miller, Mary F Mulcahy, James D Murphy, Steven Nurkin, Leonard Saltz, Sunil Sharma, David Shibata, John M Skibber, Constantinos T Sofocleous, Elena M Stoffel, Eden Stotsky-Himelfarb, Christopher G Willett, Evan Wuthrick, Kristina M Gregory, Deborah A Freedman-Cass.
Abstract
The NCCN Guidelines for Colon Cancer provide recommendations regarding diagnosis, pathologic staging, surgical management, perioperative treatment, surveillance, management of recurrent and metastatic disease, and survivorship. These NCCN Guidelines Insights summarize the NCCN Colon Cancer Panel discussions for the 2018 update of the guidelines regarding risk stratification and adjuvant treatment for patients with stage III colon cancer, and treatment of BRAF V600E mutation-positive metastatic colorectal cancer with regimens containing vemurafenib.Entities:
Mesh：
Year: 2018 PMID： 29632055 DOI： 10.6004/jnccn.2018.0021
Source DB: PubMed Journal: J Natl Compr Canc Netw ISSN： 1540-1405 Impact factor: 11.908